Healios bets on natural born killers

Healios is turning to natural killer cells (NK) to develop a range of new treatments which target solid tumours.

Regenerative medicine innovator Healios KK has announced the development of iPSC derived gene-modified NK cell development targeting solid tumors. The company is already moving ahead with its efforts to create next generation immunotherapies for solid tumors by combining its iPS cell and gene editing technology expertise.

The company’s regenerative medicine pipeline is currently pre-clinical.

Now the Japanese company is adding to the development of allogeneic, iPS cell derived gene-modified natural killer (NK) cells to its pipeline [1].

NK functions - Healios
Image of NK cell functions- Healios

Longevity.Technology: Natural killer (NK) cells are a subset of a type of white blood cell called lymphocytes. NK cells are integral to a cell mediated defence system that are naturally occurring in human bodies and attack cancer cells and virus infected cells. These NK cells have been shown to extend life, promote healing, relieve symptoms and improve the quality of life of patients; enormous potential for future growth.

Healios will develop iPSC derived cells to deliver new treatments for patients suffering from refractory cancers. They will begin promoting research and development for a next generation cancer immunotherapy using allogeneic, iPSC derived NK cells that have had specific functions reinforced using gene editing technology in order to target solid tumors. They expect to enter the Japanese and United States markets.

Healios believe they are onto a good thing. According to GBI research, the cancer immunotherapy market is set to surge over the next four years from £33bn to more than £100bn [2]. Molecular targeted agents and immunotherapy have already improved results of cancer treatment; however, the field is still in need of further treatment methods, especially when it comes to solid tumors, which appear in organs and systems other than blood.

As we’ve covered elsewhere in longevity, Healios KK are working to bring their novel regenerative therapies to market. It is, they say, is an area of tremendous unmet need and there is considerable potential.

[1] https://www.prnewswire.com/news-releases/announcement-of-ipsc-derived-gene-modified-nk-cell-development-targeting-solid-tumors-300984855.html

[2] https://www.pharmaceutical-technology.com/research-reports/cancer-immunotherapies-drugs-market/


Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

Innovating organ-on-chip to accelerate research

BIOFABICS brings custom design tools to biofabrication. While still in its infancy, organ-on-chip (OOC) technology is quickly becoming a key growth segment in the Longevity...

Cardiff University and Ervaxx turn to the dark side

Cardiff University is looking to Ervaxx and their Dark Antigens to build on research which could lead to a universal cancer treatment. Cardiff University’s world...

Young blood back on the menu

Exclusive interview: Ambrosia getting back to business after FDA warning. Research has demonstrated that giving old mice blood transfusions from younger mice shows signs of...

Precious nano metals hold key to new treatments

Metallic nanotechnology may turn out to be the most precious way to utilise metals, at least when it comes to increasing healthspan and lifespan. When...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.